Table 3.

Pharmacokinetic parameters of lansoprazole sulphone during placebo or clarithromycin treatment in homozygous EMs, heterozygous EMs and PMs for CYP2C19

		Homozygous EMs (n = 6)	Heterozygous EMs (n = 6)	PMs (n = 6)
Cmax (ng ml–1)	With placebo	161 (9, 313)##	238 (92, 384)##	743 (300, 1185)
	With clarithromycin	18 (5, 31)###	28 (8, 48)###·*	160 (99, 220)*
tmax (h)1	With placebo	1.5 (1.0–1.5)##	2.5 (1.0–3.0)#	3.5 (3.0–4.0)
	With clarithromycin	1.5 (1.5–2.0)	1.5 (1.25–3)	8.0 (2.0–12)*
AUC (0, ∞) (ng ml–1 h)	With placebo	266 (51, 481)###	557 (26, 1088)##	7789 (3372, 12207)
	With clarithromycin	47 (13, 82)###	80 (25, 136)###	2471 (1239, 3703)*
AUC ratio to lansoprazole	With placebo	0.068 (0.013, 0.12)###	0.066 (0.019, 0.11)###	0.28 (0.18, 0.39)
With clarithromycin	0.0083 (0.0003, 0.017)###*	0.0061 (0.002, 0.010)###*	0.051 (0.038, 0.063)***

Data are shown as mean and 95% confidence interval.

¹t_max is given as median (range).

^*P < 0.05,

^***P < 0.001, compared with placebo;

^#P < 0.05,

^##P < 0.01,

^###P < 0.001, compared with PMs.